A health department spokesperson says the PBAC has not decided to cap the number of cost-effectiveness analysis submissions at 32. Yet it has decided that it can only meet its legal obligations under the Act with a cap of 32 in March. Clearly, there is a cap. The question is the basis on which it is applied. …
This circular and semantic argument ends with one conclusion - a submission cap
October 31, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
WA Budget includes significant investments in health and medical research
June 20, 2025 - - Latest News -
Gilead confirms Australian submission for major HIV innovation following US approval
June 20, 2025 - - Latest News -
Advocate and founder of Rare Cancers Australia steps down as chair
June 20, 2025 - - BioPharma -
Even if 'Most Favored Nation' lowers pricing in the US, its impact on total health spending will be insignificant
June 19, 2025 - - Latest News -
Amplia announces second confirmed complete response in ACCENT trial
June 19, 2025 - - Australian Biotech -
NZ Government expands access to melatonin and psilocybin
June 18, 2025 - - Latest News -
Imugene announces US patent allowance for onCARlytics
June 18, 2025 - - Australian Biotech